Neuroendokrine Neoplasien

Klöppel, Günter

doi:10.1007/978-3-642-02322-4_35

Cited by 6 publications

(2 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NET werden noch zusätzlich, basierend auf dem proliferativen Index, in G1-, G2-und G3-Tumore graduiert [1,2]. Gastroenteropankreatische NEN zeigen in ihrer Inzidenz, in ihrem morphologischen und in ihrem molekularen Profil lokalisationsspezifische Merkmale, die vor allem bei NET teilweise sehr charakteristisch sind [4,5].…”

Section: Introductionunclassified

Histo- und Molekularpathologie bei gastroenteropankreatischen neuroendokrinen Neoplasien

Kellers,

Schulte,

Jesinghaus

et al. 2024

Dtsch Med Wochenschr

View full text Add to dashboard Cite

Section: Introductionunclassified

Histo- und Molekularpathologie bei gastroenteropankreatischen neuroendokrinen Neoplasien

Kellers,

Schulte,

Jesinghaus

et al. 2024

Dtsch Med Wochenschr

View full text Add to dashboard Cite

“…Neuroendocrine neoplasms (NEN) are a rare and strongly heterogeneous group of tumors showing variable clinicopathologic and biologic behavior. 1 They originate from neuroendocrine cells, 2 which express the vesiclecharacteristic proteins synaptophysin and chromogranin A, 3 hallmark neuroendocrine markers used for entityspecific immunohistochemical diagnosis as well as for the monitoring of disease progression. The majority of NEN is slow growing and indolent for a long period.…”

Section: Introductionmentioning

confidence: 99%

Site‐specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany

Grundmann,

Voigtländer,

Hakimhashemi

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

IntroductionNeuroendocrine neoplasms (NEN) are rare and heterogeneous epithelial tumors, occurring throughout the body. For gastroenteropancreatic (GEP)‐NEN, rising incidence rates were reported for the last decades, with underlying causes remaining largely unexplained. We evaluated NEN trends stratifying by their histologic subtypes.MethodsIncident cases of GEP‐NEN diagnosed between 2005 and 2019 were retrieved from the prospective, population‐based Bavarian Cancer Registry. GEP‐NEN were divided in their histologic subtypes, that is, neuroendocrine tumors (NET) G1, NET G2/G3, other NET versus small‐cell neuroendocrine carcinoma (NEC), large‐cell NEC, and other NEC. We calculated annual age‐standardized incidence rates (ASIRs) per 100,000 persons for the total of GEP‐NEN, NEN histologic subtypes, and tumor sites. We used an annual percentage change (APC) approach including a joinpoint analysis to investigate NEN incidence trends.ResultsASIR of GEP‐NEN rose from 2.2 in 2005 to 4.8 in 2019, characterized by a significant increase until 2012 (APC 2005–2012: 10.1%), followed by modest rise (APC 2012–2019: 1.5%). In the last decade, this increase was mainly driven by the rise of NET G1 and G2/G3, while incidence for NEC declined. Over the study period, ASIR increased significantly for all GEP‐sites except the colon. APCs were largest for the stomach, the appendix, the pancreas, and the rectum.ConclusionsThis study found a significant increase in the incidence of GEP‐NET. Though this development may partially be attributable to the increased use of advanced detection techniques and changes in NEN classification, further research should also focus on the identification of NEN risk factors.

show abstract